What is the estimated impact of these RSU grants on the company's cash flow and operating expenses?

Impact on cash flow and operating expenses

Restricted‑stock‑unit (RSU) awards are a non‑cash form of compensation. The grant of 1,875 RSUs will not drain cash at the time of issuance; instead the fair‑value of the award (the market price of the shares on the grant date) is recognized as compensation expense over the vesting schedule, typically 3‑4 years. Assuming Schrödinger’s share price was roughly $30 – $32 on Aug. 15 2025, the total fair‑value of the grant is about $56 k‑$60 k. Spread evenly over a four‑year vesting period, the incremental operating expense would be roughly $14 k‑$15 k per year, a trivial amount relative to the company’s quarterly operating expenses (which run in the low‑mid $10 million range). Consequently, the grant will have a negligible effect on cash flow and only a minimal, incremental boost to SG&A expense.

Trading implications

Because the expense impact is tiny, the RSU grant alone is unlikely to move the stock materially. However, the filing signals two things to the market: (1) the company is actively hiring senior talent and using equity to attract them, which can be viewed positively for future execution; and (2) a small dilution of ~0.02 % (1,875 / ~9 million outstanding shares) is virtually immaterial. Traders should therefore focus on broader fundamentals—revenue growth, pipeline milestones, and cash‑burn trends—rather than the modest expense hit. If the hires are in R&D or commercial leadership, any subsequent product or partnership news could provide a more actionable catalyst than the RSU expense itself. In the short term, maintain the current position unless macro or technical signals (e.g., break of key support/resistance on the SDGR chart) suggest a change.